New York, May 30, 2026, 09:23 (EDT)
Clorox shares finished the short week down hard after Chair and CEO Linda Rendle said she’s leaving for health reasons. The news put succession risk in the mix for a stock already dealing with slow sales growth and a cut profit outlook.
Clorox CLX finished Friday at $90.02, falling 6.42% for the day. That’s down about 5.4% from last week’s close of $95.11. Volume was heavier, with 4.6 million shares traded as investors sold the Oakland, California-based company behind bleach, Pine-Sol and Glad bags.
Timing is key. U.S. markets were shut Monday for Memorial Day, and the New York Stock Exchange isn’t open on Saturdays; regular hours are 9:30 a.m. to 4 p.m. ET during trading days. Investors have the weekend to look over the board search and only a few days before Clorox meets with analysts again next week.
Clorox said Thursday that Rendle has asked the board to start looking for a new CEO. She’s been with the company for 23 years. Rendle will keep her chair and CEO roles until a successor is in place and stay on as adviser for some time after, the company said. An independent board committee and an executive search firm will handle the process.
Rendle, in a personal note, said she is now cancer-free after being diagnosed with early-stage breast cancer. Ongoing treatment to prevent a recurrence has led her to reconsider her health and family plans. “Nothing changes in the short term,” she wrote. Rendle said she stays focused on strategy, execution, and the transition. The Clorox Company
Clorox stock dropped after the leadership update hit, adding to selling that started last month. The company posted flat net sales for its fiscal third quarter at $1.67 billion. Gross margin slipped to 43.2%, down from 44.6% a year ago. For fiscal 2026, Clorox is guiding for net sales to fall 6% and now sees adjusted earnings per share at $5.45 to $5.65, lower than its previous outlook.
The move was notable with the broader market climbing. The S&P 500 added 0.2% Friday and marked nine up weeks in a row. The Dow was up 0.7%. The Nasdaq gained 0.2%, with tech helping.
Clorox was hit worse than other staples stocks. Procter & Gamble was down 1.6%. Kimberly-Clark lost 2.6%. Colgate-Palmolive slipped 1.7%. The Consumer Staples Select Sector SPDR Fund, which tracks a wide group of these stocks, fell 1.8%.
Goldman Sachs’ Bonnie Herzog cut Clorox’s target price to $83 from $94, sticking with a Sell rating. Herzog said Clorox’s slight earnings beat didn’t offset weaker guidance, ongoing cost issues, the GOJO Purell integration, and the ongoing ERP software transition. ERP refers to the company’s back-office systems for managing orders, inventory, and finance. Analyst caution had already set in after Clorox’s April outlook cut.
Some on Wall Street aren’t so bearish. Morningstar analyst Erin Lash, in a May 28 note about the CEO change, called the shares “a bargain.” That could mean some investors are seeing the selloff as a chance to buy rather than a sign the story is busted. Morningstar
Clorox will be in focus this week. CEO Rendle and CFO Luc Bellet are set to appear at the dbAccess Global Consumer Conference in Paris on Wednesday, June 3, with their remarks webcast at 6 a.m. ET. Investors will be looking for comments on the executive search, updates on the GOJO deal, how gross margin pressure is playing out and if the company is sticking with its revised fiscal 2026 targets.
But there’s the risk the CEO search drags on more than investors want, or the next chief faces a rougher reset than Clorox shares suggest. A smoother handover, stronger retail buying and cost cuts might help the stock steady. But another guidance cut, softer market share or a slower GOJO deal could keep Clorox near the bottom of its 52-week range.
